Iproniazid

Last updated
Iproniazid
Iproniazid.svg
Clinical data
Trade names Marsilid, others
AHFS/Drugs.com International Drug Names
ATC code
Pharmacokinetic data
Bioavailability 1
Identifiers
  • N-isopropylisonicotinohydrazide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.199 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C9H13N3O
Molar mass 179.223 g·mol−1
3D model (JSmol)
Density 1.084 g/cm3
Boiling point 265.9 °C (510.6 °F)
  • O=C(NNC(C)C)c1ccncc1
  • InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13) Yes check.svgY
  • Key:NYMGNSNKLVNMIA-UHFFFAOYSA-N Yes check.svgY
   (verify)

Iproniazid (Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class. [1] [2] It is a xenobiotic that was originally designed to treat tuberculosis, but was later most prominently used as an antidepressant drug. However, it was withdrawn from the market because of its hepatotoxicity. [3] [4] The medical use of iproniazid was discontinued in most of the world in the 1960s, but remained in use in France until its discontinuation in 2015.

Contents

History

Iproniazid was originally developed for the treatment of tuberculosis, [1] but in 1952, its antidepressant properties were discovered when researchers noted that patients became inappropriately happy when given isoniazid, a structural analog of iproniazid. [1] [5] Subsequently N-isopropyl addition led to development as an antidepressant and was approved for use in 1958. [1] It was withdrawn in most of the world a few years later in 1961 due to a high incidence of hepatitis, and was replaced by less hepatotoxic drugs such as phenelzine and isocarboxazid. [1] Canada surprisingly withdrew iproniazid in July 1964 due to interactions with food products containing tyramine. [6] [7] Nevertheless, iproniazid has historic value as it helped establish the relationship between psychiatric disorders and the metabolism of neurotransmitters. [4]

Although iproniazid was one of the first antidepressants ever marketed, amphetamine (marketed as Benzedrine from 1935, for "mild depression", amid other indications) [8] predates it; and frankincense has been marketed traditionally for millennia for, among other things, altering mood, although it was not until 2012 that one of the components of its smoke was found to have antidepressant effects in mice. [9] [10] [11]

Structure and reactivity

The structure of iproniazid is chemically, in both structure and reactivity, similar to isoniazid. Iproniazid is a substituted hydrazine of which the isopropyl hydrazine moiety is essential for the inhibition of monoamine oxidase activity. [12]

Synthesis

This figure shows the multiple synthesis pathways towards iproniazid. Synthesis of iproniazid.png
This figure shows the multiple synthesis pathways towards iproniazid.

There are multiple routes to synthesize iproniazid. The most common precursor is methyl isonicotinate which formes isonicotinohydrazide when it reacts with hydrazine. [13] Isonicotinohydrazide can be converted into iproniazid via different pathways.

One synthesis pathway involves AcMe which results in the formation of N'-(propan-2-ylidene)isonicotinohydrazide. Subsequently, the C=N linkage is selectively hydrogenated in the presence of a platinum catalyst and with water, alcohol or acetic acid as solvent. [14] [15]

In another pathway isonicotinohydrazide reacts with either 2-bromopropane or 2-chloropropane in an N-isopropyl addition reaction to the hydrazine moiety. This directly results in the formation of iproniazid. [16] [17]

Reactions and mechanism of action

Iproniazid inhibits the activity of monoamine oxidases (MAOs) both directly and by formation of an active metabolite, isopropylhydrazine. The formation of isopropylhydrazine from iproniazid has been observed without MAOs present. [12] Both iproniazid and isopropylhydrazine react near the active site of MAOs. The reaction is a progressive first-order reaction with a high activation energy. In the presence of oxygen it is an irreversible reaction, as dehydrogenation of iproniazid at the active site of the enzyme takes place. This dehydrogenation resembles the first step of amine oxidation. After dehydrogenation iproniazid further reacts with the enzyme. [18]

Inhibition of MAOs by iproniazid is competitive and sensitive to changes in pH and temperature, similar to oxidation of the monoamine substrate. Inhibition cannot be reversed by addition of the substrate. [18] Iproniazid is able to displace non-hydrazine inhibitors, but not other hydrazine inhibitors from the active site of the enzyme. [12]

To increase the inhibition of monoamine oxidase, cyanide can be used. The reaction however remains oxygen-dependent. [18] MAO inhibition can be decreased by addition of glutathione, suggesting non enzymatic conjugation of either iproniazid or isopropylhydrazine with glutathione. [18]

Metabolism and toxicity

This figure shows the metabolism of iproniazid. The most important (proposed) metabolite is the isopropyl radical which is thought to be responsible for the heptatoxicity of iproniazid. Iproniazid Metabolism.png
This figure shows the metabolism of iproniazid. The most important (proposed) metabolite is the isopropyl radical which is thought to be responsible for the heptatoxicity of iproniazid.

Iproniazid is metabolized in the body. Iproniazid is converted to isopropyl hydrazine and isonicotinic acid in an initial hydrolysis reaction. Isopropyl hydrazine can either be released in the blood or it can be metabolically activated by microsomal CYP450 enzymes. [19] This oxidation of isopropyl hydrazine is a toxification reaction that eventually can lead to the formation of an alkylating agent: the isopropyl radical. [3] Hepatic necrosis was found in rats with doses as low as 10 mg/kg. [19]

Isopropyl radical

The presence of the isopropyl radical was indicated by another observed product of the metabolism of iproniazid: the gas propane. [3]

Alkylating agents have the capability to bind to chemical groups such as amino, phosphate hydroxyl, imidazole and sulfhydryl groups. The formed isopropyl radical is able to form S-isopropyl conjugates in vitro . This diminishes covalent binding to other proteins, however it was only observed in vitro. In vivo , hepatotoxic doses of isopropyl hydrazine, the precursor of the isopropyl radical, did not deplete sulfhydryl-group containing compounds. [3]

Liver necrosis

The isopropyl radical formed as a result of the metabolism of iproniazid, is able to covalently bind to proteins and other macromolecules in the liver. These interactions are the reason for the hepatotoxicity of iproniazid. Covalent binding results in liver necrosis by presumably changing protein function leading to organelle stress and acute toxicity. [20] [21] However, the exact mechanism of how the binding of iproniazid derivatives to liver proteins would induce liver necrosis remains unclear. [3]

Cytochrome P450 enzymes are present at the highest concentrations in the liver, causing most alkylating agents to be produced in the liver. This explains why the liver is mostly damaged by covalent binding of alkylating agents such as the isopropyl radical. [19] Rat models and other animal models have shown that cytochrome P450 enzymes convert isopropyl hydrazine to alkylating compounds that induce liver necrosis. An inducer of a class of hepatic microsomal cytochrome P450 enzymes, phenobarbital, highly increased the chance of necrosis. In contrast, the compounds cobalt chloride, piperonyl butoxide and alpha-naphthylisothiocyanate inhibit microsomal enzymes which resulted in a decreased chance of necrosis due to isopropyl hydrazine. [19]

Metabolism to other forms

Iproniazid can also be metabolised by O-dealkylation from iproniazid to acetone and isoniazid. Isoniazid can undergo further metabolism via multiple metabolic pathways, of which one eventually results in alkylating agents as well. This toxifying metabolic pathway includes N-acetylation. Reactions involving acetylation are influenced by genetic variance: the acetylator phenotype. The toxicological response to isoniazid (and thus iproniazid) can therefore be subjected to interindividual differences.

Acetone can also be produced in alternative pathway as a metabolite of isopropyl hydrazine. It is eventually converted to CO2 and exhaled. [3]

Isonicotinic acid

Isonicotinic acid, formed during the hydrolysis of iproniazid, is described as a moderately toxic compound and allergen with cumulative effects. [22] Isonicotinic acid is further metabolized by glycine-conjugation or glucuronic acid-conjugation. [19] [23]

Other toxic effects

Iproniazid can also interact with tyrosine-containing food products which may have toxic effects. [6] [7]

Excretion

Excretion can occur via different routes: via the lungs, the urine, bile and sometimes via the skin or breast milk. Iproniazid has a molecular weight of 179.219 g/mol, which is far below 500 g/mol, and it is hydrophilic (because of e.g. the N-H groups in the molecule). These two properties together indicate that iproniazid is likely to be excreted in the urine via the kidneys. [24]

Iproniazid can also be metabolized and excreted afterwards in the form of one of its metabolites which can be found in the figure above. Isoniazid is hydrophilic [24] and has a molecular weight of 137.139 g/mol. Isoniazid is therefore expected to be excreted via the urine, if it is not further metabolized in the body. The same holds for isonicotinic acid and isonicotinoyl glycine. Carbon dioxide and propane are gaseous which are presumably transported out of the body by exhalation via the lungs.

Indication

Iproniazid was originally produced as anti-tuberculosis medicine, but found to be more effective as antidepressant. When it was discovered that iproniazid is hepatotoxic, it was replaced by medicinal xenobiotics that are less harmful to the liver. Examples of antidepressant drugs that are nowadays used instead of iproniazid are isocarboxazid, phenelzine, and tranylcypromine. [3]

Drugs more effective for treatment of tuberculosis are isoniazid, pyrazinamide, ethambutol and rifampicin. [25]

Efficacy and side effects

Efficacy

Iproniazid was designed to treat tuberculosis, but its most significant positive effect is that it has a mood-stimulating property. Therefore, it was used as an antidepressant drug. [7]

Adverse effects

The most significant adverse effects of using iproniazid is the hepatotoxicity caused by its metabolites. Moreover, usage of iproniazid results in several adverse effects such as dizziness (when lying down), drowsiness, headaches, ataxia, numbness of the feet and hands, and muscular twitching. However, these adverse effects disappear after approximately 10 weeks. [26] [27]

Effects on animals

Rat animal models have been used to investigate the hepatotoxic (bio)chemical mechanism of iproniazid. A metabolite of iproniazid, isopropyl hydrazine, was found to be a potent hepatotoxin in rats. [3] [19] Hepatic necrosis was found in rats with doses as low as 10 mg/kg. [19] It was predicted with admetSAR [28] that iproniazid had a LD50 of 2.6600 mol/kg in rats. [7]

Lethality

See the table for experimentally determined LD50, TDLo and LDLo values of various organisms. [29]

OrganismTest TypeRouteReported Dose (mg/kg)Reference
DogLD50oral95Annals of the New York Academy of Sciences. Vol. 80, Pg. 626, 1959.
HumanTDLooral2.143 /DActa Neurologia et Psychiatrica Belgica. Vol. 59, Pg. 977, 1959.
HumanLDLooral14 /2W-ICanadian Medical Association Journal. Vol. 78, Pg. 131, 1958.
MonkeyLD50oral640Annals of the New York Academy of Sciences. Vol. 80, Pg. 626, 1959.
MouseLD50Intramuscular615American Review of Tuberculosis. Vol. 65, Pg. 376, 1952.
MouseLD50intraperitoneal475Japanese Journal of Pharmacology. Vol. 13, Pg. 186, 1963.
MouseLD50intravenous719American Review of Tuberculosis. Vol. 65, Pg. 376, 1952.
MouseLD50oral440Pharmaceutical Chemistry Journal Vol. 30, Pg. 750, 1996.
MouseLD50subcateneous730American Review of Tuberculosis. Vol. 65, Pg. 376, 1952.
RabbitLD50intravenous117American Review of Tuberculosis. Vol. 65, Pg. 376, 1952.
RabbitLD50oral125American Review of Tuberculosis. Vol. 65, Pg. 376, 1952.
RabbitLDLoskin2000Huntingdon Research Center Reports. Vol. -, Pg. -, 1972.
RatLD50subcutaneous538Japanese Journal of Pharmacology. Vol. 13, Pg. 186, 1963.
RatLD50unreported350Nature. Vol. 185, Pg. 532, 1960.
RatLD50oral365Journal of Pharmacology and Experimental Therapeutics. Vol. 119, Pg. 444, 1957.
RatLD50intraperitoneal375Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 363, 1970.

See also

Related Research Articles

<span class="mw-page-title-main">Monoamine oxidase inhibitor</span> Type of medication

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants, especially for treatment-resistant depression and atypical depression. They are also used to treat panic disorder, social anxiety disorder, Parkinson's disease, and several other disorders.

<span class="mw-page-title-main">Phenelzine</span> Antidepressant

Phenelzine, sold under the brand name Nardil, among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class which is primarily used as an antidepressant and anxiolytic. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.

<span class="mw-page-title-main">Phenethylamine</span> Organic compound, a stimulant in humans

Phenethylamine (PEA) is an organic compound, natural monoamine alkaloid, and trace amine, which acts as a central nervous system stimulant in humans. In the brain, phenethylamine regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1) and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons. To a lesser extent, it also acts as a neurotransmitter in the human central nervous system. In mammals, phenethylamine is produced from the amino acid L-phenylalanine by the enzyme aromatic L-amino acid decarboxylase via enzymatic decarboxylation. In addition to its presence in mammals, phenethylamine is found in many other organisms and foods, such as chocolate, especially after microbial fermentation.

<span class="mw-page-title-main">Tranylcypromine</span> Irreversible non-selective MAO inhibitor Antidepressant drug

Tranylcypromine, sold under the brand name Parnate among others, is a monoamine oxidase inhibitor (MAOI). More specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.

<span class="mw-page-title-main">Hepatotoxicity</span> Liver damage caused by a drug or chemical

Hepatotoxicity implies chemical-driven liver damage. Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval.

<span class="mw-page-title-main">Isoniazid</span> Antibiotic for treatment of tuberculosis

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.

<span class="mw-page-title-main">CYP3A4</span> Enzyme that metabolizes substances by oxidation

Cytochrome P450 3A4 is an important enzyme in the body, mainly found in the liver and in the intestine, which in humans is encoded by CYP3A4 gene. It oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the body. It is highly homologous to CYP3A5, another important CYP3A enzyme.

Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison. These pathways are a form of biotransformation present in all major groups of organisms and are considered to be of ancient origin. These reactions often act to detoxify poisonous compounds. The study of drug metabolism is called pharmacokinetics.

Toxication, toxification or toxicity exaltation is the conversion of a chemical compound into a more toxic form in living organisms or in substrates such as soil or water. The conversion can be caused by enzymatic metabolism in the organisms, as well as by abiotic chemical reactions. While the parent drug are usually less active, both the parent drug and its metabolite can be chemically active and cause toxicity, leading to mutagenesis, teratogenesis, and carcinogenesis. Different classes of enzymes, such as P450-monooxygenases, epoxide hydrolase, or acetyltransferases can catalyze the process in the cell, mostly in the liver.

<span class="mw-page-title-main">Isocarboxazid</span> Antidepressant

Isocarboxazid is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class used as an antidepressant. Along with phenelzine and tranylcypromine, it is one of only three classical MAOIs still available for clinical use in the treatment of psychiatric disorders in the United States, though it is not as commonly employed in comparison to the others.

<span class="mw-page-title-main">Moclobemide</span> Antidepressant

Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.

<span class="mw-page-title-main">Nialamide</span> Antidepressant

Nialamide is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant. It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.

<span class="mw-page-title-main">N-acetyltransferase</span> Class of enzymes

N-acetyltransferase (NAT) is an enzyme that catalyzes the transfer of acetyl groups from acetyl-CoA to arylamines, arylhydroxylamines and arylhydrazines. They have wide specificity for aromatic amines, particularly serotonin, and can also catalyze acetyl transfer between arylamines without CoA. N-acetyltransferases are cytosolic enzymes found in the liver and many tissues of most mammalian species, except the dog and fox, which cannot acetylate xenobiotics.

<span class="mw-page-title-main">4-Hydroxyamphetamine</span> Group of stereoisomers

4-Hydroxyamphetamine (4HA), also known as hydroxyamfetamine, hydroxyamphetamine, oxamphetamine, norpholedrine, para-hydroxyamphetamine, and α-methyltyramine, is a drug that stimulates the sympathetic nervous system.

<span class="mw-page-title-main">Enzyme inhibitor</span> Molecule that blocks enzyme activity

An enzyme inhibitor is a molecule that binds to an enzyme and blocks its activity. Enzymes are proteins that speed up chemical reactions necessary for life, in which substrate molecules are converted into products. An enzyme facilitates a specific chemical reaction by binding the substrate to its active site, a specialized area on the enzyme that accelerates the most difficult step of the reaction.

<span class="mw-page-title-main">Aldehyde oxidase</span> Enzyme

Aldehyde oxidase (AO) is a metabolizing enzyme, located in the cytosolic compartment of tissues in many organisms. AO catalyzes the oxidation of aldehydes into carboxylic acid, and in addition, catalyzes the hydroxylation of some heterocycles. It can also catalyze the oxidation of both cytochrome P450 and monoamine oxidase (MAO) intermediate products. AO plays an important role in the metabolism of several drugs.

<span class="mw-page-title-main">Safinamide</span> Reversible monoamine oxidase B inhibitor

Safinamide is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.

<span class="mw-page-title-main">Hydrazine (antidepressant)</span> Group of antidepressants

The hydrazine antidepressants are a group of non-selective, irreversible monoamine oxidase inhibitors (MAOIs) which were discovered and initially marketed in the 1950s and 1960s. Most have been withdrawn due to toxicity, namely hepatotoxicity, but a few still remain in clinical use.

<span class="mw-page-title-main">4-Ipomeanol</span> Chemical compound

4-Ipomeanol (4-IPO) is a pulmonary pre-toxin isolated from sweet potatoes infected with the fungus Fusarium solani. One of the 4-IPO metabolites is toxic to the lungs, liver and kidney in humans and animals. This metabolite can covalently bind to proteins, thereby interfering with normal cell processes.

References

  1. 1 2 3 4 5 Maxwell RA, Eckhardt SB (1990). "Iproniazid". Drug Discovery. Humana Press. pp.  143–154. ISBN   9780896031807.
  2. ↑ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical Pharmacology. 35 (8): 1381–1387. doi:10.1016/0006-2952(86)90285-6. PMID   2870717.
  3. 1 2 3 4 5 6 7 8 9 Timbrell J (2008). Taylor & Francis Group. pp. 324–326. doi:10.3109/9781420007084. ISBN   978-0-8493-7302-2.
  4. 1 2 Henn F, Sartorius N, Helmchen H, Lauter H, eds. (2013-11-11). Contemporary Psychiatry. Springer Science & Business Media. p. 109. ISBN   9783642595196.
  5. ↑ Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK (April 2011). "Antidepressants: From MAOIs to SSRIs and more". Indian Journal of Psychiatry. 53 (2): 180–182. doi: 10.4103/0019-5545.82567 . PMC   3136031 . PMID   21772661.
  6. 1 2 Alex A, Harris CJ, Smith DA (2015-10-26). Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward. John Wiley & Sons. ISBN   9781118819449.
  7. 1 2 3 4 "Iproniazid". www.drugbank.ca. Retrieved 2018-03-27.
  8. ↑ Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". Journal of Psychopharmacology. 27 (6): 479–496. doi:10.1177/0269881113482532. PMC   3666194 . PMID   23539642.
  9. ↑ Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, et al. (August 2008). "Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain". FASEB Journal. 22 (8): 3024–3034. doi: 10.1096/fj.07-101865 . PMC   2493463 . PMID   18492727.
  10. ↑ Moussaieff A, Gross M, Nesher E, Tikhonov T, Yadid G, Pinhasov A (December 2012). "Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals". Journal of Psychopharmacology. 26 (12): 1584–1593. doi:10.1177/0269881112458729. PMID   23015543. S2CID   1675621.
  11. ↑ Drahl C (22 December 2008). "Frankincense And Myrrh". Chemical & Engineering News. 86 (51): 38. doi:10.1021/cen-v086n051.p038. ISSN   0009-2347.
  12. 1 2 3 Smith TE, Weissbach H, Udenfriend S (1963). "Studies on Monoamine Oxidase: The Mechanism of Inhibition of Monoamine Oxidase by Iproniazid". Biochemistry. 2 (4): 746–751. doi:10.1021/bi00904a021. PMID   14075108.
  13. ↑ Pozsgay V, Jennings HJ (1987). "Azide synthesis with stable nitrosyl salts". Tetrahedron Letters. 28 (43): 5091–5092. doi:10.1016/s0040-4039(00)95598-9.
  14. ↑ Yale HL, Losee K, Martins J, Holsing M, Perry FM, Bernstein J (1953). "Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds1,2". Journal of the American Chemical Society. 75 (8): 1933–1942. doi:10.1021/ja01104a046.
  15. ↑ Vigorita MG, Ottanà R, Maccari R, Monforte F, Bisignano G, Pizzimenti FC (1998). "Synthesis and in vitro antimicrobial and antitumoral screening of novel lipophilic isoniazid analogues. VI". Bollettino Chimico Farmaceutico. 137 (7): 267–276. PMID   9795482.
  16. ↑ Journal of the American Pharmaceutical Association (1912-1977), 42: 457,463
  17. ↑ Società chimica italiana (1997) [c. 1871]. "Gazzetta chimica Italiana". European Journal of Organic Chemistry. 88: v.393, 398. ISSN   0016-5603.
  18. 1 2 3 4 Davison AN (October 1957). "The mechanism of the irreversible inhibition of rat-liver monoamine oxidase by iproniazid (marsilid)". The Biochemical Journal. 67 (2): 316–322. doi:10.1042/bj0670316. PMC   1200154 . PMID   13471553.
  19. 1 2 3 4 5 6 7 8 Nelson SD, Mitchell JR, Snodgrass WR, Timbrell JA (September 1978). "Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine". The Journal of Pharmacology and Experimental Therapeutics. 206 (3): 574–585. PMID   702322.
  20. ↑ Iorga A, Dara L, Kaplowitz N (May 2017). "Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis". International Journal of Molecular Sciences. 18 (5): 1018. doi: 10.3390/ijms18051018 . PMC   5454931 . PMID   28486401.
  21. ↑ Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB (October 1973). "Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism". The Journal of Pharmacology and Experimental Therapeutics. 187 (1): 185–194. PMID   4746326.
  22. ↑ Tsarichenko GV, Bobrov VI, Smarkov MV (1977-04-01). "Toxicity of isonicotinic acid". Pharmaceutical Chemistry Journal. 11 (4): 481–483. doi:10.1007/BF01156485. ISSN   0091-150X. S2CID   9309017.
  23. ↑ Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, et al. (January 2012). "A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct". Antimicrobial Agents and Chemotherapy. 56 (1): 28–35. doi:10.1128/AAC.05486-11. PMC   3256082 . PMID   22037847.
  24. 1 2 de Sagher RM, De Leenheer AP, Claeys AE (June 1976). "Identification and quantitative GLC determination of iproniazid in human urine". Journal of Pharmaceutical Sciences. 65 (6): 878–882. doi:10.1002/jps.2600650619. PMID   932974.
  25. ↑ Te Brake LH, de Knegt GJ, de Steenwinkel JE, van Dam TJ, Burger DM, Russel FG, et al. (January 2018). "The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box". Annual Review of Pharmacology and Toxicology. 58 (1): 271–291. doi: 10.1146/annurev-pharmtox-010617-052438 . PMID   28715978.
  26. ↑ Lichtenstein MR, Mizenberg E (May 1954). "A controlled study of isoniazid and iproniazid". Diseases of the Chest. 25 (5): 573–579. doi:10.1378/chest.25.5.573. PMID   13151011.
  27. ↑ "Side Effects of Iproniazid". edudrugs.com. Retrieved 2018-03-27.
  28. ↑ Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. (November 2012). "admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties". Journal of Chemical Information and Modeling. 52 (11): 3099–3105. doi:10.1021/ci300367a. PMID   23092397. S2CID   16356154.
  29. ↑ lookchem.com/Iproniazid
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.